TY - JOUR
T1 - Lessons from a decade of adult vaccine rollout in low- and middle-income countries
T2 - a scoping review
AU - Gerste, Amelia K.
AU - Majidulla, Arman
AU - Baidya, Anurima
AU - Georgewill, Onimitein
AU - Deluca, Andrea
AU - Pelzer, Puck T.
AU - Gill, Michelle M.
AU - Jerene, Degu
AU - Buis, Joeri S.
AU - Kerkhoff, Andrew D.
AU - Limaye, Rupali J.
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Introduction: The historical focus of vaccines on child health coupled with the advent of novel vaccines targeting adult populations necessitates exploring strategies for adult vaccine implementation. Areas covered: This scoping review extracts insights from the past decade’s experiences introducing adult vaccines in low- and middle-income countries. Among 25 papers reviewed, 19 focused on oral cholera vaccine, 2 on Meningococcal A vaccines, 2 on tetanus toxoid vaccine, 1 on typhoid vaccine, and 1 on Ebola vaccine. Aligned with WHO’s Global Framework for New TB Vaccines for Adults and Adolescents, our findings center on vaccine availability, accessibility, and acceptance. Expert Opinion: Availability findings underscore the importance of understanding disease burden for prioritization, multi-sectoral collaboration during planning, and strategic resource allocation and coordination. Accessibility results highlight the benefits of leveraging existing health infrastructure and adequately training healthcare workers, and contextually tailoring vaccine delivery approaches to reach challenging sub-groups like working male adults. Central to fostering acceptance, resonant sensitization, and communication campaigns engaging the communities and utilizing trusted local leaders countered rumors and increased awareness and uptake. As we approach the introduction of a new adult TB vaccine, insights from this review equips decision-makers with key evidence-based recommendations to support successful and equitable vaccinations targeting adults.
AB - Introduction: The historical focus of vaccines on child health coupled with the advent of novel vaccines targeting adult populations necessitates exploring strategies for adult vaccine implementation. Areas covered: This scoping review extracts insights from the past decade’s experiences introducing adult vaccines in low- and middle-income countries. Among 25 papers reviewed, 19 focused on oral cholera vaccine, 2 on Meningococcal A vaccines, 2 on tetanus toxoid vaccine, 1 on typhoid vaccine, and 1 on Ebola vaccine. Aligned with WHO’s Global Framework for New TB Vaccines for Adults and Adolescents, our findings center on vaccine availability, accessibility, and acceptance. Expert Opinion: Availability findings underscore the importance of understanding disease burden for prioritization, multi-sectoral collaboration during planning, and strategic resource allocation and coordination. Accessibility results highlight the benefits of leveraging existing health infrastructure and adequately training healthcare workers, and contextually tailoring vaccine delivery approaches to reach challenging sub-groups like working male adults. Central to fostering acceptance, resonant sensitization, and communication campaigns engaging the communities and utilizing trusted local leaders countered rumors and increased awareness and uptake. As we approach the introduction of a new adult TB vaccine, insights from this review equips decision-makers with key evidence-based recommendations to support successful and equitable vaccinations targeting adults.
KW - Adult vaccines
KW - adult vaccine implementation
KW - low- and middle-income countries
KW - tuberculosis vaccine
KW - vaccine acceptability
KW - vaccine accessibility
KW - vaccine availability
KW - vaccine introductions
UR - http://www.scopus.com/inward/record.url?scp=85198454013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198454013&partnerID=8YFLogxK
U2 - 10.1080/14760584.2024.2375329
DO - 10.1080/14760584.2024.2375329
M3 - Review article
C2 - 38967117
AN - SCOPUS:85198454013
SN - 1476-0584
VL - 23
SP - 688
EP - 704
JO - Expert review of vaccines
JF - Expert review of vaccines
IS - 1
ER -